On April 6, the U.S. Food and Drug Administration held a public meeting on Patient-Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on “symptoms and the daily impacts of their condition, current approaches to treatment, and decision factors taken into account when selecting a treatment.”
The U.S. Food and Drug Administration is seeking people with sarcopenia to share their comments at a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia on April 6, from 1 p.m. to 5 p.m. EST.
The Aging in Motion (AIM) Coalition recently hosted a webinar about the ICD-10 code for sarcopenia, titled "An ICD-10 Code for Sarcopenia: Implications for Diagnosis and Clinical Practice." An archived video of the webinar is now available.
In 2016, the Aging in Motion Coalition’s (AIM) proposal to establish an ICD-10-CM code for sarcopenia was accepted by the Centers for the Disease Control and Prevention. To provide additional insight into the process and its importance, AIM will be hosting a one-hour webinar on January 24, 2017.
The Aging in Motion (AIM) Coalition hosted its second annual meeting with U.S. Food and Drug Administration (FDA) leaders and leading scientists, industry representatives, and advocates to discuss developments and advances in clinical research and treatment of sarcopenia in Bethesda, Md.
A major way the Alliance advances science is through building coalitions of diverse organizations and individuals to bring visibility and support to health research, with the ultimate goal of improving the healthy length and quality of life for everyone. Learn more.
Sign up for our email newsletter, Living Longer & Loving It, for the latest information on scientific research on aging and health.